Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

ClinicalTrials.gov ID: NCT00197080

Public ClinicalTrials.gov record NCT00197080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome

Study identification

NCT ID
NCT00197080
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
380 participants

Conditions and interventions

Interventions

  • Ropinirole Extended Release (XR) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2005
Primary completion
Not listed
Completion
Dec 31, 2005
Last update posted
Sep 22, 2016

2005 – 2006

United States locations

U.S. sites
60
U.S. states
26
U.S. cities
58
Facility City State ZIP Site status
GSK Investigational Site Alabaster Alabama 35007
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Mesa Arizona 85201
GSK Investigational Site Peoria Arizona 85381 - 4828
GSK Investigational Site Phoenix Arizona 85032
GSK Investigational Site Sun City Arizona 85351
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Northridge California 91325
GSK Investigational Site Oxnard California 93030
GSK Investigational Site Pasadena California 91105
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site San Diego California 92103
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Colorado Springs Colorado 80909
GSK Investigational Site Denver Colorado 80212
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site Largo Florida 33773
GSK Investigational Site Pembroke Pines Florida 33026
GSK Investigational Site Stuart Florida 34996
GSK Investigational Site Atlanta Georgia 30338
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Austell Georgia 30106
GSK Investigational Site Dawsonville Georgia 30534
GSK Investigational Site Macon Georgia 31201
GSK Investigational Site Woodstock Georgia 30189
GSK Investigational Site Northbrook Illinois 60062
GSK Investigational Site Lenexa Kansas 66214
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Louisville Kentucky 40217
GSK Investigational Site Baton Rouge Louisiana 70808
GSK Investigational Site Newton Massachusetts 02459
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Albuquerque New Mexico 87108
GSK Investigational Site Albany New York 12205
GSK Investigational Site Endwell New York 13760
GSK Investigational Site Kingston New York 12401
GSK Investigational Site Schenectady New York 12308
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Cincinnati Ohio 45236
GSK Investigational Site Cleveland Ohio 44130
GSK Investigational Site Dublin Ohio 43017
GSK Investigational Site Westerville Ohio 43081
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Portland Oregon 97219
GSK Investigational Site Lafayette Hill Pennsylvania 19444
GSK Investigational Site Columbia South Carolina 29201
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Jackson Tennessee 38305
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Salt Lake City Utah 84102
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Alexandria Virginia 22311
GSK Investigational Site Charlottesville Virginia 22911
GSK Investigational Site Bellingham Washington 98226
GSK Investigational Site Renton Washington 98055
GSK Investigational Site Spokane Washington 99204
GSK Investigational Site Walla Walla Washington 99362
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00197080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00197080 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →